BRaf inhibitors, dabrafenib and SB590885, enhance ERK1/2 signalling in cardiomyocytes and increase angiotensin II-induced cardiac hypertrophy.

29 April 2017 (08:30 - 17:30)
Organised by:
Congress Presentation Part of: Poster Session 1 - Basic Science - Therapeutic approach Cell Signalling HFA Premium Access Heart Failure 2017 - 4th World Congress on Acute Heart Failure

About the speaker

Photo

University of Reading, Reading (United Kingdom of Great Britain & Northern Ireland)

9 More presentations in this session

Presentation thumbnail
Mr J. Margaria (Turin, IT)
Presentation thumbnail
Doctor F. Vasques-Novoa (Porto, PT)
Presentation thumbnail
Doctor C. Baez Diaz (Madrid Caceres, ES)
Presentation thumbnail
Professor L. Zhang (Shanghai, CN)
Presentation thumbnail
Doctor A. Kazakov (Homburg, DE)

ESC 365 is supported by

ESC 365 is supported by